Evidence map›Paper›PMID 34623758›Full record

ArticleUnited European gastroenterology journal2021

High prevalence of extended-spectrum beta-lactamase organisms and the COVID-19 pandemic impact on donor recruitment for fecal microbiota transplantation in Hong Kong.

Yuk Kam Yau, Wing Yan Joyce Mak, Nok Shun Rashid Lui, Wai Yin Rita Ng, Choi Yan Kitty Cheung, Ying Lee Amy Li, Yuet Ling Jessica Ching, Miu Ling Chin, Ho Shing Louis Lau, Ka Leung Francis Chan and 2 more

Open access · hybridAbstract read
In one paragraph

Article in United European gastroenterology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. [Expert consensus on the clinical application of gut microbiota transplant therapy in chronic liver disease (version 2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  3. Review
  4. Outcomes of Fecal Microbiota Transplantation forOpen forum infectious diseases · 2025
    Article
  5. Assuring safety of fecal microbiota transplantation in the COVID-19 era: A single-center experience.JGH open : an open access journal of gastroenterology and hepatology · 2023
    Article
  6. The Impact of COVID-19 Pandemic on ESBL-ProducingAntibiotics (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Promises of microbiome-based therapies.Journal of hepatology · 2022
    Review
  9. Article
  10. Article
  11. Stools' donor recruitment, a challenge in pandemic times.United European gastroenterology journal · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yuk Kam YauCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-2865-5992
Wing Yan Joyce MakCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0001-5221-7349
Nok Shun Rashid LuiDepartment of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Wai Yin Rita NgCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Choi Yan Kitty CheungCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Ying Lee Amy LiCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Yuet Ling Jessica ChingCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Miu Ling ChinCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Ho Shing Louis LauDepartment of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Ka Leung Francis ChanCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Kay Sheung Paul ChanCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Siew Chien NgCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-6850-4454
Chinese University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith increasing number of clinical trials relating to fecal microbiota transplantation (FMT), it is crucial to identify and recruit long-term, healthy, and regular fecal donors.

objectiveWe aimed to report the outcomes of screening and recruitment of fecal donors for FMT.

methodsPotential donors were recruited via advertisement through internal mass emails at a university. They were required to undergo a pre-screening telephone interview, a detailed questionnaire, followed by blood and stool investigations.

resultsFrom January 2017 to December 2020, 119 potential donors were assessed with 75 failed pre-screening. Reasons for failure included: inability to come back for regular and long-term donation (n = 19), high body mass index (n = 17), underlying chronic illness or on long-term medications (n = 11), being healthcare professionals (n = 10), use of antibiotics within 3 months (n = 5) and others (n = 13). Forty-four donors completed questionnaires and 11 did not fulfill the clinical criteria. Of the remaining 33 potential donors who had stool and blood tests, 21 failed stool investigations (19 extended-spectrum beta-lactamase [ESBL] organisms, one Clostridioides difficile, one C. difficile plus Methicillin Resistant Staphylococcus aureus), one failed blood tests (high serum alkaline phosphatase level), one required long-term medication and nine withdrew consent and/or lost to follow-up. In total, only one out of 119 (0.8%) potential donors was successfully recruited as a regular donor.

conclusionThere was a high failure rate in donor screening for FMT. Main reasons for screening failure included high prevalence of positive ESBL organisms in stool and failed commitment to regular stool donation.

Indexed as

Donor SelectionFecal Microbiota TransplantationAdolescentAdultbeta-LactamasesCOVID-19FecesFemaleHong KongHumansMaleMiddle AgedPandemicsPrevalenceYoung Adultbeta-LactamasesCOVID-19 pandemicdonor recruitmentESBL organismsextended-spectrum beta-lactamasefecal donorfecal microbiota transplantation

Identifiers

PMID34623758
PMCPMC8598959
OpenAlexW3201748403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.